We retrospectively analyzed the outcome of 67 patients with breast (n ¼ 24), ovarian (n ¼ 11) or testicular cancer (n ¼ 32) treated for relapse after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplantation. Treatment, survival and toxicity were analyzed. Patients with breast, ovarian or testicular cancer received a mean of 5.9 (range 1-24), 5.1 (1-13) and 4.6 (1-13) regimens for relapse after HDC. Overall response at the end of the observation period was 20.8% for patients with breast cancer (three complete (CR) and two partial responses (PR)), 45.5% (one CR, four PR) for ovarian and 9.4% (three PR) for testicular cancer patients. The mean overall-survival (OAS) from first relapse was 28 (range 3-44), 17 (2-24) and 10 (1-28) months, respectively. Leukocytopenia grade 3/4 occurred in 27-63% of patients, and thrombocytopenia grade 3/4 was observed in 58-88%, respectively. Nonhematological grade 3/4 toxicities were below 20%. In conclusion, patients with relapse after HDC usually have a poor outcome but long-term survivors are observed. Hematological toxicity is common, while other severe side effects are less frequent.
In the last decade, high-dose chemotherapy (HDC) with stem cell support for patients with solid tumors has steadily increased and about 3300 patients were treated in Europe in 1999, most of them receiving autologous transplants. 1 Despite some decrease during the last years because of discouraging results, especially for patients with breast cancer, [2] [3] [4] there is an increasing number of patients who have relapsed after HDC. However, there is little information in the literature about this poor-risk group of patients and many prospective trials exclude such patients making standardized treatment recommendations even more difficult. HDC means maximum physical and mental stress for these patients and the occurrence of relapse after this heavy treatment remains a challenge for their physicians. We have therefore analyzed the clinical outcome of 67 patients with solid tumors who had relapsed after HDC with peripheral blood stem cell (PBSC) support, to study possible treatment options, survival and the toxicities of the regimens used.
Patients and methods

Eligibility
Patients with breast (n ¼ 24), ovarian (n ¼ 11) or testicular cancer (n ¼ 32) who had received HDC with PBSC transplantation at our clinic and who subsequently relapsed were included in this retrospective analysis. Patient characteristics are summarized in Table 1 .
High-dose chemotherapy and stem cell transplantation
The following HDC regimens were used:
Breast cancer -cyclophosphamide (CYC) 6000 mg/m ; CEC. Collection, cryopreservation and thawing of stem cells has been described in detail elsewhere. 5 PBSC were transfused 48 h after completion of HDC followed by s.c. granulocytecolony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) until leukocyte recovery. Engraftment was defined as the day post-PBSC transfusion ( ¼ day 1) when the WBC count reached 1000/ ml and when the platelets were stableX20 000/ml at least 2 days after the last platelet transfusion.
Evaluation
The charts of eligible patients were retrospectively evaluated for all treatment modalities from the start of HDC.
Each surgical procedure, radiotherapy to a certain site or systemic therapy (chemotherapy, hormonal therapy, immunotherapy) performed after relapse was counted as one regimen. Response and duration of response were evaluated based on radiological (X-ray, CT-scan, MRT, ultrasound), clinical and laboratory results as documented in the patients' charts and according to the WHO and UICC criteria, respectively. Toxicity was assessed based on the National Cancer Institute Common Toxicity Criteria (NCI CTC). The mean observation time for all patients was 53 months (range 11-101 months) from diagnosis until death or end of observation (from five patients the exact date of diagnosis was not available). Progression-free survival (PFS) after HDC was counted from the beginning of the first high-dose regimen.
Statistical methods
Survival curves were generated by the method of KaplanMeier using the SPSS 10.0 software (Chicago, IL, USA). For calculation of mean values, standard deviations, medians and correlation coefficients the Microsoft Excel 2000 software (Microsoft, Redmond, WA, USA) was used.
Results
High-dose chemotherapy
The HDC regimens given are listed above and the mean time between diagnosis and HDC and the number of courses of HDC given are shown in Table 1 . After HDC and PBSC transplantation, patients with breast cancer recovered their WBC and platelets at day 11 (range 9-16) and day 12 (10-25), respectively. The corresponding values for patients with ovarian cancer were day 10 (range 8-13) and 11 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) ) and for those with testicular cancer day 11 (range 8-13) and 12 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , respectively. There was no correlation between the number of HDC courses or WBC and platelet engraftment and survival (r À0.30 to +0.32 for any correlation).
The mean time between HDC and first relapse was 9.4 months (range 0-46 months), 3.1 months (range 0-12 months) and 2.1 months (range 0-48 months) for patients with breast, ovarian and testicular cancer, respectively. There was some correlation between PFS after HDC and overall survival (OAS) in patients with breast and testicular cancer (r ¼ 0.73 and 0.80) but not in those with ovarian cancer (r ¼ 0.34).
Therapy for relapse after HDC and PBSC transplantation
In patients with breast, ovarian or testicular cancer, a mean of 3.5 (range 1-10), 3.9 (1-9) and 3.3 (1-8) cases of progression were documented and 5.9 (range 1-24), 5.1 (1-13) and 4.6 (1-13) different treatment regimens per patient were used for relapse. The different modalities are shown in Figure 1 .
Response and survival
At the end of the observation period, five of 24 patients with breast cancer (20.8%) had responded to therapy (three complete response (CR), two partial response (PR)). Among patients with ovarian cancer (n ¼ 11), one CR and four PR were observed for an overall response rate of 45.5%, while three PR (9.4%) were found among the 32 men with testicular cancer. Disease stabilization was observed in five patients with breast (20.8%), three patients with testicular (9.4%) and in none with ovarian cancer. Table 2 summarizes the best responses for the most frequently used systemic treatment regimens.
Mean OAS after HDC was 31 months for the whole group of patients (range 3-69 months), 50 months for breast (range 8-69 months), 25 months for ovarian (range 5-32 months) and 18 months for testicular cancer Figure 2 ). In total, 17 patients with breast (71%), six patients with ovarian (55%) and eight with testicular cancer (25%) were still alive at the end of the observation period and 58% (breast cancer), 27% (ovarian cancer) and 16% (testicular cancer) of the patients survived at least 24 months.
Toxicity
Hematological grade 3 and 4 toxicities occurred in 13-88% of the patients. Other side effects were less frequent, and 33% (breast cancer), 18% (ovarian cancer) and 16% (testicular cancer) of the patients showed no grade 3 and 4 toxicities at all. Table 3 summarizes the most frequent events. 
Discussion
The benefit of HDC in patients with solid tumors is not yet fully clarified and there have been conflicting results especially in patients with breast and ovarian cancer, [6] [7] [8] [9] [10] [11] while there seems to be an improved outcome for patients with advanced or relapsed germ cell tumors. 12, 13 Irrespective of the benefit of such intensive treatment modalities, physicians have to deal with an increasing number of patients who have relapsed after HDC and stem cell transplantation. Since there are no standardized recommendations in this situation, we retrospectively analyzed the course of 67 patients with breast, ovarian and testicular cancer, who had relapsed after HDC and were treated at our unit. Although the three entities cannot be compared, we decided to choose this patient population to get more insight into what happens when patients with solid tumors fail after HDC.
At the present there is very little information in the literature about treatment for patients with relapse after HDC and stem cell transplantation. Waselenko et al have retrospectively analyzed data from 74 patients with breast cancer who had relapsed after HDC with stem cell transplantation. Depending on the number of HDC given, relapse-free interval, and on whether the patients received salvage therapy or not, survival after post-transplant relapse ranged from 7.7-19.7 months. Patients receiving tandem HDC and those with a longer relapse-free interval (412 months) had a better outcome than their counterparts. Most strikingly, there was a clear benefit of salvage therapy leading to an increase of mean post-transplant relapse survival from 6.8 to 13.8 months (Po0.0001). 14 Owing to the rather small number of patients we did not undertake any subgroup analysis. The mean OAS for our patients with breast cancer was 28 months, which was the best result among the three diagnoses. The superior outcome, as compared with the results mentioned above, might result from different patient characteristics, the small number of patients and different treatment modalities but underlines the rationale for performing salvage therapy in these patients.
Patients with ovarian cancer showed the best overallresponse (one CR, four PR, 45.5%). Although only 11 patients were studied, these results are similar to those reported by Cook et al, 15 when 10 out of 19 women (53%) responded to one of six different first-line salvage therapies after relapse following HDC. The median OAS after relapse was 12.8 months for the 16 patients (84%) still alive, as compared to 10.5 months for six out of 11 patients (55%) alive in our group.
Patients with relapsing germ cell tumors represented the largest group and had the poorest outcome of all patients analyzed. Our results were inferior to those reported by Kollmannsberger et al, 16 when 16 of 56 patients (29%) relapsing after HDC with PBSC transplantation responded favorably to salvage therapy (including additional HDC with PBSC support in 14 patients) with a median survival of 27 months as compared to a 9.4% response rate and a mean OAS of 10 months for our patients. However, 29 of 32 patients (91%) treated at our hospital progressed during Relapse after high-dose chemotherapy P Bojko et al or immediately after HDC and PBSC transplantation with a mean time to progression of only 2.1 vs 6 months in the study mentioned above. Therefore, these patients might represent a subgroup with a very unfavorable prognosis. Bokemeyer et al 17 reported response in three of 22 patients (14%) who had relapsed after HDC and stem cell transplantation, and were treated with gemcitabine in a phase II study. Similar results were achieved with oxaliplatin (12% response rate in patients failing to respond to prior HDC). 18 Response rate and time to progression are important parameters to evaluate the benefit of a certain treatment regimen, while OAS is also influenced by subsequent treatment too. The purpose of our analysis was not to recommend a certain therapy for patients with relapse after HDC and stem cell transplantation but to see which therapy can still be offered in such a situation, which side effects occur and how long patients will survive. Combined or sequential therapy seem to be useful options for achieving individual treatment optimization, as could be demonstrated by some long-term survivors. Chemotherapy was the most frequently used modality (84%), followed by radiotherapy (51%) and surgery (39%). The mean number of different treatment regimens ranged from 4.6 for patients with testicular cancer to 5.9 for breast cancer patients. Therapy should be performed according to established risk-adapted algorithms for metastatic disease, particularly in patients with breast cancer. 19 Since patients with solid tumors were shown to have slow trilineage hematological recovery, 20 bone marrow toxicity of subsequent chemotherapy must be taken into account. Leukocytopenia and thrombocytopenia grades 3 and 4 occurred in 61 and 75% of all patients, respectively, and was most pronounced in patients with testicular cancer, while nonhematological toxicity did not differ from that seen in other patients. Thus, adequate selection and dosing of systemic chemotherapy are necessary to prevent persisting cytopenia with subsequent delay of therapy. Gemcitabine, vinorelbine and 5-fluorouracil were among the most frequently used cytostatic drugs and are usually well tolerated, but thrombocytopenia (gemcitabine) and neutropenia (vinorelbine) are common.
In conclusion, therapy should be offered to patients with relapse following HDC and stem cell transplantation. Despite the poor prognosis, long-term survivors are observed. Hematological toxicity is pronounced, while other side effects are manageable. Treatment can be performed according to the results of clinical trials with other patients but should be administered by experienced oncologists. Studies in this setting are warranted to further improve the outcome of this high-risk group of patients.
